PINK:MKGAF

Merck Kommanditgesellschaft Auf Aktien Stock News

etoro logo Buy MKGAF
*Your capital is at risk
$164.15
+2.94 (+1.82%)
At Close: Jul 10, 2026
Merck KGaA (MKKGY) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Merck KGaA (OTC:MKKGY) (OTC:MKGAF) on Thursday agreed to acquire Bio-Techne Corporation (NASDAQ:TECH) in an all-cash transaction valued at approximately $11.3 billion, as the German science and techno
Bio-Techne stock jumps, with Germany's Merck KGaA buying the company at a 24% premium.
Merck KGaA has ​agreed to acquire ‌biotech firm Bio-Techne Corp ​for $73 per ​share in cash, ⁠the German ​science and ​healthcare firm said in a statement ​on ​Thursday.

Germany's Merck to Buy Bio-Techne for $11 Billion

06:08am, Thursday, 25'th Jun 2026
Merck KGaA offered $73 a share in cash to buy Bio-Techne, representing a 24% premium to the U.S. lab-tools supplier's closing price Wednesday.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
Merck KGaA (MKKGY) Q1 2026 Earnings Call Transcript

Merck KGaA Q1 Earnings Call Highlights

10:08am, Wednesday, 13'th May 2026
Merck KGaA ETR: MRK reported what executives described as a “solid start” to 2026, with organic growth in its Life Science and Electronics businesses offsetting a decline in Healthcare, and raised
Merck KGaA (MKKGY) came out with quarterly earnings of $0.59 per share, beating the Zacks Consensus Estimate of $0.45 per share. This compares to earnings of $0.59 per share a year ago.
DARMSTADT, Germany--(BUSINESS WIRE)--Merck KGaA, Darmstadt, Germany, a leading global science and technology company, today announced the first patient was dosed in the Phase 3 program, ELOWEN-1 (NCT0
Merck KGaA is rated a 'Buy' with a revised price target of €127/share, reflecting strong fundamentals and resilient business segments. I expect 2026 to be a transition year with AEPS decline due to
Earnings and Valuation This table compares Athersys and Merck KGaA"s gross revenue, earnings per share and valuation. Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
U.S. President Donald Trump pledged to make prescription drugs cheaper for Americans than anywhere in the world, but his TrumpRx.gov website is not delivering across the board lower prices than those
Institutional and Insider Ownership 0.1% of Merck KGaA shares are held by institutional investors. 6.6% of Calithera Biosciences shares are held by company insiders. Strong institutional ownership is
Merck KGaA (MKKGY) Q4 2025 Earnings Call Transcript
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE